ANALYSIS AND ADVOCACY, NOT LEGAL ADVICE — cannabinoid scheduling varies by state, is changing fast, and a compound lawful federally may be a felony locally; do not act on these pages without your own counsel. Seven pages: the statutory landscape after the 2018 Farm Bill, the Federal Analogue Act and the "substantially similar" doctrine, the prong-by-prong case that the side-chain homologs are not analogues, the 2025 appropriations redefinition and its 0.4 mg per-container threshold, the market and product-safety consequences, the analogue treadmill and the Federal Register record showing that compound-by-compound prohibition selects for more dangerous compounds, and a state research-positioning argument.
7 pages · 77 citations (7 without a resolved identifier, marked on the page) · updated 2026-09-27
What this section is, and what it is not
Education and harm reduction. Not medical, legal or financial advice. Every factual claim carries a source; contested and single-source claims are marked as such on the page.
The boundary. This section teaches separation, purification, formulation, dosing arithmetic and analytical chemistry with real parameters, because withholding that detail from someone who will proceed anyway is the harm this library exists to prevent. It does not publish preparative routes for converting one cannabinoid into a more intoxicating one; those are described structurally and cited to the literature, without procedures.
Pages
ANALYSIS AND ADVOCACY, NOT LEGAL ADVICE. The federal architecture that governs hemp-derived cannabinoids: the 2018 definition of hemp at 7 U.S.C. § 1639o, the marijuana definition at 21 U.S.C. § 802(16), the measurement question (total THC versus delta-9 only) that actually decides compliance, DEA's 2020 interim final rule on synthetically derived tetrahydrocannabinols, the Ninth Circuit's contrary reading in AK Futures, the 2025 appropriations redefinition with its 12 November 2026 effective date, and the independent and contradictory movement of the states.
11 sections · policy
ANALYSIS AND ADVOCACY, NOT LEGAL ADVICE. The Controlled Substance Analogue Enforcement Act at 21 U.S.C. § 813 and the definition at § 802(32)(A): the three prongs set out properly, the split over whether prong (i) is a mandatory conjunct, the void-for-vagueness litigation from Forbes through Washam, Klecker, Hodge and Turcotte, the knowledge element after McFadden v. United States, the fact that "substantially similar" has never been given a chemical definition by Congress or by regulation, and Alexander Shulgin's critique of that phrase.
9 sections · policy
ANALYSIS AND ADVOCACY, NOT LEGAL ADVICE. The core argument, prong by prong, that the long-side-chain homologs of delta-9 THC are not controlled substance analogues: the structural case from side-chain structure-activity relationships, the a fortiori point that CBD is structurally closer to delta-9 THC than the homologs are and is lawful, the honest assessment that the effects prong is the weakest limb, the representation prong after McFadden, the phytocannabinoid versus cannabimimetic distinction, the historical-precedent argument and its verification gaps — and what cuts against the position.
13 sections · policy
ANALYSIS AND ADVOCACY, NOT LEGAL ADVICE. The appropriations provision that rewrites the federal definition of hemp: the move from a delta-9-only percentage to a total tetrahydrocannabinols standard including THCA, the quantifiable threshold of 0.4 mg total THC per container, the exclusion of cannabinoids not naturally produced by the plant or synthesised outside it, the delayed effective date of 12 November 2026, the container-versus-serving question, and why a milligram-per-container standard is a fundamentally different regulatory object from a percentage by dry weight.
9 sections · policy
ANALYSIS AND ADVOCACY, NOT LEGAL ADVICE. What follows from setting a per-container threshold one to two orders of magnitude below the existing market: the arithmetic against typical product potencies, displacement of demand from tested and labelled supply to untested supply as a product-safety consequence rather than merely an economic one, substitution toward more potent novel cannabinoids under a potency-blind threshold, the enforcement gap created by uncontrolled precursors, and the counter-argument a regulator would make.
9 sections · policy
ANALYSIS AND ADVOCACY, NOT LEGAL ADVICE. The general law underneath the substitution argument, and the evidence for it: scheduling a compound does not remove it from a market, it selects for a successor with more effect per unit of detectable mass. The Federal Register is the government's own documentation of each turn, and the page sets it out in date order for the synthetic cannabinoids, for the phenethylamines through to the NBOMe series, and for the opioids through to the nitazenes. It closes with the enforcement-architecture case — the DEA Office of Diversion Control, Joe Rannazzisi, and the 2016 Act that raised the standard for acting against distributors — because that is what shows the pressure being aimed at the compliant layer rather than at the harm vector.
9 sections · policy
ANALYSIS AND ADVOCACY, NOT LEGAL ADVICE. The positioning argument: Colorado's recreational market drove terpene profiling, strain-specific effect claims and full-spectrum product science, while a hemp-agriculture state is positioned instead for chemotype genetics, analytical capacity, reference-standard development and the characterisation of rare and homolog cannabinoids. Presented as a research-and-industry argument, with the caveat that state positioning rests on state law that is actively changing — and that analytical and agricultural capability survives a legal change while a product category does not.
5 sections · policy